“The world’s first life-saving gene therapy for children, developed by GlaxoSmithKline and Italian scientists, was approved for sale in Europe on Friday, in a step forward for the pioneering technology to fix faulty genes.
Called Strimvelis, it is designed for a tiny number of children with ADA Severe Combined Immune Deficiency (ADA-SCID). SCID is sometimes known as “bubble baby” disease, since those born with it have immune systems so weak they must live in germ-free environments.
Strimvelis is the second gene therapy to be approved in Europe, after UniQure’s Glybera, which treats a rare adult blood disorder.”
Share this entry
- Dr. Raysa Echeverria, DC is appointed to the American Health Council’s Board of Physicians November 14, 2018
- American Health Council Appoints Adam David, PT, DPT to its Board of Physical Therapy November 14, 2018
- Mark Russo, MD is Honored by the American Health Council for “Best in Medicine” November 14, 2018
- Dr. Jeffrey Pammer, DC is appointed onto the Board of Physicians by the American Health Council. November 13, 2018
- Diana Mercurio, BS, RPH, CDE, CDOE, CVDOE is Appointed to the American Health Council’s Industry Board November 13, 2018
- The American Health Council appoints Dr. Martin Meinig, MD to the Board of Physicians November 10, 2018